The bipartisan co-chairs of a congressional psychedelics caucus are touting the Food and Drug Administration’s (FDA) new draft guidance on researching substances like psilocybin and MDMA.
Reps. Lou Correa (D-CA) and Jack Bergman (R-MI), who founded the Psychedelics Advancing Therapies (PATH) Caucus last year, applauded the agency in a joint statement on Wednesday, commending FDA for “their considerable work in releasing the non-binding guidance for comment regarding the clinical study and development of psychedelic therapies for those suffering from mental and behavioral health conditions.”
They noted that FDA has already designated psilocybin and MDMA as “breakthrough therapies” for the treatment of severe depression and post-traumatic stress disorder (PTSD), respectively.
“As our country continues to suffer tragic rates of suicide and opioid overdose deaths, which disproportionately impact our Nation’s military Veterans, it is critical that policymakers such as those in our caucus pursue additional pragmatic measures—alongside the relevant agencies—to ensure that those who would benefit most from these potentially lifesaving therapies can get access as soon as possible,” the congressmen said.
The release of the draft guidance came just days after another set of bipartisan lawmakers filed a bill that specifically asked the agency to take that step.
Reps. Dan Crenshaw
Read full article on Marijuana Moment
